Scholarlink

Background <p>Mineral trioxide aggregate (MTA) is the gold standard pulpotomy agent with some shortcomings, such as lengthy setting&#xa0;time, difficult manipulation, and a costly price. A new bioactive material, ACTIVA BioACTIVE Base/Liner, may prevail over these drawbacks.</p> Aim <p>The purpose of the study was to evaluate and compare the pulp reaction in primary teeth to ACTIVA BioACTIVE Base/Liner and conventional powder-liquid MTA (WhiteProRoot®MTA) as pulpotomy agents.</p> Materials and methods <p>Eighty primary first molars in children aged 7–9&#xa0;years were assigned into two groups (40 molars/group) in which the pulpotomy procedure was done. The pulp tissue was dressed in ACTIVA BioACTIVE Base/Liner (group I) and MTA (group II). Twenty teeth from each group were extracted after 15&#xa0;days, and the remaining twenty teeth in each group were extracted after 30&#xa0;days. All teeth specimens underwent a decalcification treatment for histological and immunohistochemical assessment for fibronectin and osteopontin (OPN) expressions.</p> Results <p>Significant statistical differences were identified between ACTIVA BioACTIVE and MTA groups concerning the total scoring of pulp vascularity, pulp fibrosis, and presence or absence of pulp stone (<i>P</i> = 0.015, <i>P</i> &lt; 0.001, <i>P</i> = 0.038, respectively), whereas a non-significant difference was noted concerning the odontoblastic layer organization. Fibronectin and OPN in both ACTIVA BioACTIVE and MTA groups were positive at the fibrotic and calcified areas.</p> Conclusion <p>ACTIVA BioACTIVE Base/Liner demonstrated encouraging outcomes concerning&#xa0;enhanced systemic tissue responses.</p> Trial Registration <p>ClinicalTrials.gov, NCT05300152, “Pulpotomy Medications in Primary Teeth”, Registered: 29/03/2022, <a href="https://clinicaltrials.gov/study/NCT05300152?cond=NCT05300152&amp;rank=1">https://clinicaltrials.gov/study/NCT05300152?cond=NCT05300152&amp;rank=1</a></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histopathological and immunohistochemical characterization of pulp tissue reaction to ACTIVA BioACTIVE base/liner in primary teeth pulpotomy: a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月3日

查看全文
  • Shaimaa M. Mahfouz Omer,
  • Heba Abdul Fattah Elsaied,
  • Wafaa Yahia Alghonemy,
  • Shaimaa S. EL-Desouky

摘要

Background

Mineral trioxide aggregate (MTA) is the gold standard pulpotomy agent with some shortcomings, such as lengthy setting time, difficult manipulation, and a costly price. A new bioactive material, ACTIVA BioACTIVE Base/Liner, may prevail over these drawbacks.

Aim

The purpose of the study was to evaluate and compare the pulp reaction in primary teeth to ACTIVA BioACTIVE Base/Liner and conventional powder-liquid MTA (WhiteProRoot®MTA) as pulpotomy agents.

Materials and methods

Eighty primary first molars in children aged 7–9 years were assigned into two groups (40 molars/group) in which the pulpotomy procedure was done. The pulp tissue was dressed in ACTIVA BioACTIVE Base/Liner (group I) and MTA (group II). Twenty teeth from each group were extracted after 15 days, and the remaining twenty teeth in each group were extracted after 30 days. All teeth specimens underwent a decalcification treatment for histological and immunohistochemical assessment for fibronectin and osteopontin (OPN) expressions.

Results

Significant statistical differences were identified between ACTIVA BioACTIVE and MTA groups concerning the total scoring of pulp vascularity, pulp fibrosis, and presence or absence of pulp stone (P = 0.015, P < 0.001, P = 0.038, respectively), whereas a non-significant difference was noted concerning the odontoblastic layer organization. Fibronectin and OPN in both ACTIVA BioACTIVE and MTA groups were positive at the fibrotic and calcified areas.

Conclusion

ACTIVA BioACTIVE Base/Liner demonstrated encouraging outcomes concerning enhanced systemic tissue responses.

Trial Registration

ClinicalTrials.gov, NCT05300152, “Pulpotomy Medications in Primary Teeth”, Registered: 29/03/2022, https://clinicaltrials.gov/study/NCT05300152?cond=NCT05300152&rank=1